ClinicalTrials.gg
CompletedNCT02486809Updated Nov 2, 2016

A Bioequivalence Study of Subcutaneous (SC) Lebrikizumab Administered by Needle and Syringe or by Prefilled Syringe With Needle Safety Device (PFS-NSD)

A Phase 1 interventional study of Lebrikizumab in Healthy Volunteer, sponsored by Genentech, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-11-02.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will assess the bioequivalence in healthy participants between a high-concentration formulation of lebrikizumab withdrawn from a vial and administered SC as a single injection by a needle and syringe, and a low-concentration formulation of lebrikizumab administered SC as a single injection via PFS-NSD.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.

First submitted after Genentech, Inc. became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults 18 to 65 years of age, inclusive
  • (BMI) 18 to 32 kg/m\^2 and body weight 50 to 100 kg, inclusive
  • Nonpregnant and nonlactating females
  • Agreement to utilize effective among men and women of

Exclusion criteria

Exclusion Criteria:

  • Known allergy or to study drug or components
  • History of alcohol or drug abuse within 12 months prior to study drug, or positive test for alcohol or drugs of abuse
  • Receipt of an agent within 30 days of 5 half-lives prior to Day -1
  • Biological therapy within 90 days prior to Day -1
  • Parasitic or Listeria monocytogenes infection within 6 months prior to Screening
  • Receipt of blood products within 2 months prior to study entry
  • Donation or loss of blood/plasma within up to 6 months prior to study drug, depending upon volume
  • Receipt of within 1 month prior to study drug
  • Use of tobacco- or nicotine-containing products within 14 days prior to Screening
  • Use of any prescription or nonprescription medication within 14 days prior to study drug
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
176 participants (actual)

Study arms

  • Experimental
    Treatment 1: Needle and Syringe

    Healthy volunteers will receive a single SC injection of lebrikizumab, withdrawn from a vial and administered by a needle and syringe.

    Drug: Lebrikizumab

  • Experimental
    Treatment 2: PFS-NSD

    Healthy volunteers will receive a single SC injection of lebrikizumab, administered by PFS-NSD.

    Drug: Lebrikizumab

Interventions

  • Participants will receive a single SC dose of lebrikizumab, delivered via needle and syringe or PFS-NSD.

06

What researchers measure

Primary outcomes

  1. Maximum observed concentration (Cmax) of lebrikizumab

    Time frame: Pre-dose and post-dose from Day 1 until study completion or premature withdrawal (up to approximately 3 months)

  2. Time to maximum concentration (Tmax) of lebrikizumab

    Time frame: Pre-dose and post-dose from Day 1 until study completion or premature withdrawal (up to approximately 3 months)

  3. Area under the concentration-time curve to the last measurable concentration (AUC0-last) of lebrikizumab

    Time frame: Pre-dose and post-dose from Day 1 until study completion or premature withdrawal (up to approximately 3 months)

  4. Area under the concentration-time curve extrapolated to infinity (AUC0-inf) of lebrikizumab

    Time frame: Pre-dose and post-dose from Day 1 until study completion or premature withdrawal (up to approximately 3 months)

  5. Apparent terminal elimination rate constant of lebrikizumab

    Time frame: Pre-dose and post-dose from Day 1 until study completion or premature withdrawal (up to approximately 3 months)

  6. Apparent terminal elimination half-life (t1/2) of lebrikizumab

    Time frame: Pre-dose and post-dose from Day 1 until study completion or premature withdrawal (up to approximately 3 months)

  7. Apparent clearance (CL/F) of lebrikizumab

    Time frame: Pre-dose and post-dose from Day 1 until study completion or premature withdrawal (up to approximately 3 months)

  8. Apparent volume of distribution (Vz/F) of lebrikizumab

    Time frame: Pre-dose and post-dose from Day 1 until study completion or premature withdrawal (up to approximately 3 months)

Secondary outcomes

  1. Incidence of adverse events

    Time frame: From Day -1 until study completion or premature withdrawal (up to approximately 3 months)

  2. Incidence of anti-therapeutic antibodies (ATAs) to lebrikizumab

    Time frame: From Day 1 until study completion or premature withdrawal (up to approximately 3 months)

07

Study locations

4 sites
  • Daytona Beach, Florida 32117, United States
  • Evansville, Indiana 47710, United States
  • Dallas, Texas 75247, United States
  • Madison, Wisconsin 53704, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2015, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2015
First posted
Jul 1, 2015
Start
Jul 2015
Primary completionActual
Oct 2015
CompletionActual
Oct 2015
Last update
Nov 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02486809
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Jul 1, 2015
Start date
Jul 2015
Primary completion
Oct 2015
Completion
Oct 2015
Last update
Nov 2, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lebrikizumab

Start the discussion